Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Promyelocytic Leukemia
Study results from C. Billottet and colleagues update understanding of acute promyelocytic leukemia
March 24th, 2009
"We have investigated the role of phosphoinositide 3-kinases (PI3Ks) in the in vitro pathophysiology of acute promyelocytic leukemia (APL) and in the response to treatment with all-trans-retinoic-acid (ATRA), utilizing a range of novel inhibitors that target individual or all catalytic class I isoforms of PI3K (p110 alpha, p110 beta, p110 delta, and p110 gamma). ATRA-induced phosphorylation of the Akt kinase and ribosomal S6 protein in APL cells was sensitive to class I PI3K, and p110 beta or p110 delta inhibitors, and to the mammalian target of rapamycin (mTOR) inhibitor rapamycin," scientists in London, the United Kingdom report. "In primary APL, inhibition of p110...
Source: Cancer Weekly (2009-03-24)
|
